 Mi-Hyun Nam
Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epithelial-Mesenchymal Transition | 3 | 2021 | 220 | 1.590 |
Why?
| | Astrocytes | 5 | 2026 | 228 | 1.580 |
Why?
| | Ocular Hypertension | 2 | 2022 | 70 | 1.380 |
Why?
| | Glaucoma | 3 | 2023 | 251 | 1.330 |
Why?
| | Lens, Crystalline | 3 | 2023 | 136 | 1.240 |
Why?
| | Transforming Growth Factor beta2 | 2 | 2021 | 33 | 1.200 |
Why?
| | Epithelial Cells | 3 | 2021 | 1135 | 1.160 |
Why?
| | Capsule Opacification | 2 | 2020 | 22 | 1.140 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2025 | 15 | 0.920 |
Why?
| | Retinal Vessels | 1 | 2025 | 77 | 0.870 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2025 | 194 | 0.790 |
Why?
| | Diabetic Retinopathy | 1 | 2025 | 211 | 0.760 |
Why?
| | Reperfusion Injury | 1 | 2025 | 292 | 0.740 |
Why?
| | Crystallins | 2 | 2023 | 61 | 0.700 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2021 | 33 | 0.680 |
Why?
| | Posterior Capsule of the Lens | 1 | 2020 | 11 | 0.620 |
Why?
| | Retinal Ganglion Cells | 4 | 2025 | 123 | 0.590 |
Why?
| | Endothelial Cells | 1 | 2025 | 878 | 0.590 |
Why?
| | CA1 Region, Hippocampal | 1 | 2019 | 50 | 0.580 |
Why?
| | Receptors, Opioid, mu | 1 | 2019 | 66 | 0.570 |
Why?
| | Endothelium, Vascular | 1 | 2025 | 956 | 0.570 |
Why?
| | Glycation End Products, Advanced | 1 | 2018 | 81 | 0.510 |
Why?
| | Memory | 1 | 2019 | 297 | 0.500 |
Why?
| | Cerebral Cortex | 1 | 2020 | 474 | 0.490 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 346 | 0.490 |
Why?
| | Aspirin | 1 | 2020 | 406 | 0.480 |
Why?
| | Recovery of Function | 1 | 2020 | 716 | 0.460 |
Why?
| | Histones | 1 | 2020 | 666 | 0.410 |
Why?
| | Monoamine Oxidase | 2 | 2025 | 27 | 0.390 |
Why?
| | Disease Models, Animal | 7 | 2025 | 4568 | 0.380 |
Why?
| | Mice | 9 | 2025 | 18358 | 0.360 |
Why?
| | Stroke | 1 | 2020 | 1271 | 0.330 |
Why?
| | Animals | 13 | 2026 | 38106 | 0.320 |
Why?
| | Intraocular Pressure | 2 | 2022 | 330 | 0.310 |
Why?
| | Fibronectins | 2 | 2021 | 136 | 0.310 |
Why?
| | Optic Nerve Injuries | 1 | 2025 | 9 | 0.220 |
Why?
| | Nerve Growth Factors | 1 | 2025 | 79 | 0.220 |
Why?
| | Chelating Agents | 1 | 2025 | 76 | 0.220 |
Why?
| | Cells, Cultured | 2 | 2025 | 4151 | 0.210 |
Why?
| | Capillaries | 1 | 2025 | 125 | 0.210 |
Why?
| | Axons | 1 | 2025 | 204 | 0.200 |
Why?
| | Optic Nerve Diseases | 1 | 2023 | 49 | 0.190 |
Why?
| | Blotting, Western | 1 | 2025 | 1184 | 0.190 |
Why?
| | Acetylation | 2 | 2023 | 259 | 0.190 |
Why?
| | Presbyopia | 1 | 2023 | 15 | 0.190 |
Why?
| | Axonal Transport | 1 | 2022 | 26 | 0.190 |
Why?
| | Rats | 4 | 2025 | 5585 | 0.180 |
Why?
| | Neuroprotection | 1 | 2022 | 46 | 0.180 |
Why?
| | Zinc | 1 | 2025 | 307 | 0.180 |
Why?
| | Heat-Shock Proteins | 1 | 2022 | 139 | 0.180 |
Why?
| | NF-kappa B | 1 | 2025 | 667 | 0.170 |
Why?
| | Spinal Cord Injuries | 1 | 2025 | 235 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 143 | 0.170 |
Why?
| | Molecular Chaperones | 1 | 2022 | 199 | 0.160 |
Why?
| | Monoamine Oxidase Inhibitors | 1 | 2020 | 20 | 0.160 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2020 | 72 | 0.150 |
Why?
| | Nerve Degeneration | 1 | 2020 | 49 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2020 | 85 | 0.150 |
Why?
| | Pyramidal Cells | 1 | 2020 | 80 | 0.150 |
Why?
| | GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 20 | 0.150 |
Why?
| | Dopaminergic Neurons | 1 | 2020 | 68 | 0.150 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2019 | 37 | 0.140 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5995 | 0.140 |
Why?
| | Rats, Sprague-Dawley | 2 | 2025 | 2525 | 0.140 |
Why?
| | Actins | 1 | 2020 | 426 | 0.130 |
Why?
| | Apoptosis | 1 | 2025 | 2445 | 0.120 |
Why?
| | Signal Transduction | 2 | 2021 | 5226 | 0.120 |
Why?
| | Motor Activity | 1 | 2020 | 718 | 0.110 |
Why?
| | Humans | 10 | 2026 | 145785 | 0.110 |
Why?
| | Glucose | 1 | 2020 | 1050 | 0.110 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2025 | 154 | 0.100 |
Why?
| | Cell Line | 1 | 2020 | 2823 | 0.100 |
Why?
| | Male | 6 | 2025 | 73012 | 0.100 |
Why?
| | Brain | 1 | 2026 | 2969 | 0.100 |
Why?
| | Cell Movement | 1 | 2018 | 963 | 0.100 |
Why?
| | Parkinson Disease | 1 | 2020 | 601 | 0.100 |
Why?
| | Models, Biological | 1 | 2020 | 1764 | 0.090 |
Why?
| | Mice, Knockout | 1 | 2019 | 3130 | 0.090 |
Why?
| | Gliosis | 1 | 2026 | 30 | 0.060 |
Why?
| | Nerve Crush | 1 | 2025 | 8 | 0.060 |
Why?
| | Ciliary Neurotrophic Factor | 1 | 2025 | 12 | 0.060 |
Why?
| | Picolinic Acids | 1 | 2025 | 8 | 0.060 |
Why?
| | Receptor, trkB | 1 | 2025 | 39 | 0.060 |
Why?
| | Neuroprotective Agents | 1 | 2025 | 149 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2025 | 499 | 0.050 |
Why?
| | Disulfides | 1 | 2023 | 94 | 0.050 |
Why?
| | Solubility | 1 | 2023 | 240 | 0.050 |
Why?
| | Cell Survival | 1 | 2025 | 1105 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2023 | 450 | 0.040 |
Why?
| | Lysine | 1 | 2023 | 305 | 0.040 |
Why?
| | Immobility Response, Tonic | 1 | 2020 | 6 | 0.040 |
Why?
| | Mice, Inbred ICR | 1 | 2020 | 113 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2023 | 572 | 0.040 |
Why?
| | Water | 1 | 2023 | 448 | 0.040 |
Why?
| | Nanoparticles | 1 | 2025 | 517 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2020 | 450 | 0.030 |
Why?
| | Down-Regulation | 1 | 2020 | 618 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2865 | 0.030 |
Why?
| | Aged | 2 | 2023 | 26217 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8347 | 0.020 |
Why?
| | Middle Aged | 1 | 2020 | 36309 | 0.010 |
Why?
| | Female | 1 | 2020 | 79045 | 0.010 |
Why?
|
|
Nam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|